- Opinion
- [Reporter’s View] Biotech’s confidence and responsibility
- by Son, Hyung-Min Mar 14, 2024 05:42am
- Several biotechnology companies in South Korea have suffered major setbacks while pursuing first-in-class new technology businesses. GenNBio, a company known for xenotransplantation of pancreatic islets, is currently facing the possibility of being dissolved. Due to management disputes, the departure of key R&D personnel, financial diffic
- Opinion
- [Reporter’s View] Need momentum to boost investments
- by Kim, Jin-Gu Mar 12, 2024 05:49am
- Investment in the domestic pharma-bio industry is slowly rising, awakening from its long winter slumber. Although it is still too early to call it a full spring compared to the boom the industry had enjoyed in 2021-2022, however, significant signs of recovery are being shown through various indicators. Such change is usually most often n
- Opinion
- [Reporter’s View] Potential drawbacks of expanding RSAs
- by Lee, Tak-Sun Mar 12, 2024 05:49am
- It has been announced that more drugs will be added to the Risk Sharing Agreements (RSAs) track, which will help to improve patient access and reduce uncertainties. In December, the ‘Improvement of the Drug Pricing System to Ensure Fair-value Compensation for Innovative New Drugs and Healthcare Security’ was announced. Under this syste
- Opinion
- [Reporter’s View] On MFDS’s new drug management team
- by Lee, Hye-Kyung Mar 6, 2024 06:03am
- A new drug management support team will be established under the Ministry of Food and Drug Safety’s Pharmaceutical Safety Bureau. According to the 'Partial Amendment of the Enforcement Rules of the Ministry of Food and Drug Safety and its Affiliated Institutions' that was released by the MFDS on February 7, the MFDS will newly establish a d
- Opinion
- [Reporter’s View] Long-awaited, but not prescribed?
- by Eo, Yun-Ho Feb 8, 2024 05:49am
- Even though the only existing treatment on the planet has finally been approved for reimbursement in Korea, prescribers are hesitant to introduce the drug to their institutions due to concerns over incurring losses if the costly drugs are not used. These are drugs that have gained much attention since approval. The drugs showed outstandin
- Opinion
- [Reporter’s View] Handling AI-collected ‘cancer info’
- by Kim, Jin-Gu Feb 6, 2024 06:10am
- Medical AI company Lunit announced on the 5th that it will be participating in the establishment of an internet-only bank. Lunit will join the U-BANK consortium, including Lendit, Jobis & Villains, Travel Wallet, and Hyundai Marine & Fire Insurance, to establish Korea’s fourth internet-only bank. An interesting part of the information
- Opinion
- [Desk’s View] New principles rouse moral responsibility
- by Lee, Tak-Sun Feb 6, 2024 06:10am
- The government’s reevaluation of approved and listed drugs is in full swing. The stated purpose is to filter out ineffective drugs and provide coverage to better ones. As this is very necessary for the public, it is the government's responsibility to fulfill this task. The reevaluation is being conducted omnidirectionally by the Ministry
- Opinion
- [Reporter’s View] Restructuring in pharmaceutical industry
- by Son, Hyung-Min Feb 5, 2024 07:27pm
- Korea’s biopharmaceutical industry is facing corporate restructuring. Both global and Korean pharmaceutical companies are undergoing aggressive employee reductions. AstraZeneca Korea is implementing a voluntary resignation as a follow-up measure related to the withdrawal of Forxiga, a diabetes treatment, from the Korean market. The com
- Opinion
- [Reporter’s View] Conglomerates expanding into the pharma
- by Kim, Jin-Gu Jan 26, 2024 05:51am
- M&A activities have made headlines in the pharmaceutical and biotechnology (pharma and biotech) industries in early 2024. Hanmi Pharmaceutical, a leader in the Korean pharmaceutical industry, has officially confirmed its merger with OCI group, a chemical company. Additionally, Orion has acquired LegoChem Biosciences, a globally recognized
- Opinion
- [Reporter’s View] KRPIA's new BOD signifies fresh starts
- by Eo, Yun-Ho Jan 25, 2024 05:49am
- Following its fresh start with new staff members and a restructured board of directors, KRPIA is stabilizing its operations. Previously, Korean Research-based Pharmaceutical Industry Association (KRPIA) faced increasing concerns regarding its operations, primarily involving leadership vacancy. The decrease in the number of board members c
